Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD

38.12  -0.19 (-0.5%)

Fundamental Rating

8

Taking everything into account, EXEL scores 8 out of 10 in our fundamental rating. EXEL was compared to 549 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. These ratings could make EXEL a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

EXEL had positive earnings in the past year.
EXEL had a positive operating cash flow in the past year.
In the past 5 years EXEL has always been profitable.
In the past 5 years EXEL always reported a positive cash flow from operatings.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

With an excellent Return On Assets value of 22.49%, EXEL belongs to the best of the industry, outperforming 97.45% of the companies in the same industry.
The Return On Equity of EXEL (29.62%) is better than 97.45% of its industry peers.
With an excellent Return On Invested Capital value of 25.22%, EXEL belongs to the best of the industry, outperforming 98.36% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is below the industry average of 14.75%.
The last Return On Invested Capital (25.22%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

EXEL has a better Profit Margin (27.01%) than 96.17% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
EXEL has a better Operating Margin (33.71%) than 98.00% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
With an excellent Gross Margin value of 96.59%, EXEL belongs to the best of the industry, outperforming 95.99% of the companies in the same industry.
In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 11.62 indicates that EXEL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.62, EXEL belongs to the best of the industry, outperforming 87.80% of the companies in the same industry.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.62
ROIC/WACC2.62
WACC9.62%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

EXEL has a Current Ratio of 3.51. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL's Current ratio of 3.51 is in line compared to the rest of the industry. EXEL outperforms 40.98% of its industry peers.
EXEL has a Quick Ratio of 3.44. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Quick ratio (3.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.74% over the past year.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.73%.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.20% on average per year.
The Revenue is expected to grow by 10.31% on average over the next years. This is quite good.
EPS Next Y26.98%
EPS Next 2Y24.9%
EPS Next 3Y25.55%
EPS Next 5Y22.2%
Revenue Next Year7.93%
Revenue Next 2Y10.23%
Revenue Next 3Y12%
Revenue Next 5Y10.31%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 18.33, EXEL is valued on the expensive side.
94.54% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.84.
EXEL is valuated correctly with a Price/Forward Earnings ratio of 13.21.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.81% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.29. EXEL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 18.33
Fwd PE 13.21
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.72% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaper than 96.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.61
EV/EBITDA 11.38
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 25.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.68
PEG (5Y)1.45
EPS Next 2Y24.9%
EPS Next 3Y25.55%

More info and screens

0

5. Dividend

5.1 Amount

EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (8/18/2025, 1:33:03 PM)

38.12

-0.19 (-0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners95.32%
Inst Owner Change-0.47%
Ins Owners2.23%
Ins Owner Change12.41%
Market Cap10.26B
Analysts77.69
Price Target46.28 (21.41%)
Short Float %6.85%
Short Ratio5.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)9.81%
PT rev (3m)19.56%
EPS NQ rev (1m)0.72%
EPS NQ rev (3m)4.54%
EPS NY rev (1m)0%
EPS NY rev (3m)3.69%
Revenue NQ rev (1m)-0.5%
Revenue NQ rev (3m)1.61%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.46%
Valuation
Industry RankSector Rank
PE 18.33
Fwd PE 13.21
P/S 4.6
P/FCF 13.61
P/OCF 13.29
P/B 5.05
P/tB 5.21
EV/EBITDA 11.38
EPS(TTM)2.08
EY5.46%
EPS(NY)2.89
Fwd EY7.57%
FCF(TTM)2.8
FCFY7.35%
OCF(TTM)2.87
OCFY7.52%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.68
PEG (5Y)1.45
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 11.62
F-Score8
WACC9.62%
ROIC/WACC2.62
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y26.98%
EPS Next 2Y24.9%
EPS Next 3Y25.55%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.93%
Revenue Next 2Y10.23%
Revenue Next 3Y12%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year42.25%
EBIT Next 3Y34.74%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%